Cargando…

Case Report: Diagnosis of Mucopolysaccharidosis Type IVA With Compound Heterozygous Galactosamine-6 Sulfatase Variants and Biopsy of Replaced Femoral Heads

INTRODUCTION: Mucopolysaccharidosis Type IVA (MPS IVA) or Morquio A Syndrome, is a rare metabolic disorder caused by compromised galactosamine-6 sulfatase (GALNS) encoded by GALNS gene (NM_000512.5), leading to keratin sulfate (KS), and chondroitin-6-sulfate accumulation in various organs. We presen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yiyang, Peng, Hao, Hsiang, Fuchou, Fang, Haoyu, Du, Dajiang, Jiang, Chenyi, Wang, Yehui, Chen, Chun, Zhang, Changqing, Gao, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289150/ https://www.ncbi.nlm.nih.gov/pubmed/35859948 http://dx.doi.org/10.3389/fped.2022.914889

Ejemplares similares

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Role of elosulfase alfa in mucopolysaccharidosis IVA
por: Regier, Debra S, et al.
Publicado: (2016)

Atypical presentation of mucopolysaccharidosis type IVA
por: Rush, Eric T.
Publicado: (2016)

Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
por: Sawamoto, Kazuki, et al.
Publicado: (2020)

Bio-Plex immunoassay measuring the quantity of lysosomal N-acetylgalactosamine-6-sulfatase protein in dried blood spots for the screening of mucopolysaccharidosis IVA in newborn: a pilot study
por: Chuang, Chih-Kuang, et al.
Publicado: (2017)

Endoscopic and Image Analysis of the Airway in Patients with Mucopolysaccharidosis Type IVA
por: Lee, Yi-Hao, et al.
Publicado: (2023)

Cochlear implantation in a patient with mucopolysaccharidosis IVA
por: Nagao, Kyoko, et al.
Publicado: (2019)

Pathophysiology of Hip Disorders in Patients with Mucopolysaccharidosis IVA
por: Wang, Zhigang, et al.
Publicado: (2020)

Bone Growth Induction in Mucopolysaccharidosis IVA Mouse
por: Rintz, Estera, et al.
Publicado: (2023)

Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks
por: Leal, Andrés Felipe, et al.
Publicado: (2023)

Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2014)

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
por: Ficicioglu, Can, et al.
Publicado: (2020)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy
por: Li, Ying, et al.
Publicado: (2022)

Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
por: Politei, Juan, et al.
Publicado: (2021)

Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA
por: Lee, Seung Hoon, et al.
Publicado: (2022)

Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA
por: Lee, Na Hee, et al.
Publicado: (2012)

Determination of genotypic and clinical characteristics of Colombian patients with mucopolysaccharidosis IVA
por: Tapiero-Rodriguez, Sandra M, et al.
Publicado: (2018)

Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA
por: Álvarez, Víctor J., et al.
Publicado: (2020)

Mucopolysaccharidosis Type IVA: Extracellular Matrix Biomarkers in Cardiovascular Disease
por: Montavon, Brittany, et al.
Publicado: (2022)

Enzyme Replacement in a Human Model of Mucopolysaccharidosis IVA In Vitro and Its Biodistribution in the Cartilage of Wild Type Mice
por: Dvorak-Ewell, Melita, et al.
Publicado: (2010)

Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma
por: Zhang, Jin, et al.
Publicado: (2023)

Erratum: Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA
por: Lee, Na Hee, et al.
Publicado: (2013)

Muskoskeletal manifestations of mild form of mucopolysaccharidosis iva - a clinical case
por: Ganeva, Margarita, et al.
Publicado: (2014)

Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model
por: Sawamoto, Kazuki, et al.
Publicado: (2019)

Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy
por: Chen, Hui, et al.
Publicado: (2021)

Hip Dysplasia in Mucopolysaccharidosis Type IVA (Morquio A Syndrome) Treated by Proximal Femoral Valgization Osteotomy: A Case Report
por: Berger-Groch, Josephine, et al.
Publicado: (2018)

Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis
por: Lee, Chung-Lin, et al.
Publicado: (2022)

Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II
por: Chkioua, Latifa, et al.
Publicado: (2011)

Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report
por: Vasilevska, Lauma, et al.
Publicado: (2022)

Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA
por: Hendriksz, Christian J., et al.
Publicado: (2012)

Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome)
por: Kampmann, Christoph, et al.
Publicado: (2016)

Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA
por: Chin, Sharon J., et al.
Publicado: (2020)

Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI
por: Tulebayeva, Assel, et al.
Publicado: (2020)

Structural Basis of Mucopolysaccharidosis Type II and Construction of a Database of Mutant Iduronate 2-Sulfatases
por: Saito, Seiji, et al.
Publicado: (2016)

A boy with mucopolysaccharidosis type II accompanied with a novel variation in heparan-N-sulfatase
por: Li, Yu-Jue, et al.
Publicado: (2019)

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
por: Harmatz, Paul, et al.
Publicado: (2010)

Enhanced Efficiency of the Basal and Induced Apoptosis Process in Mucopolysaccharidosis IVA and IVB Human Fibroblasts
por: Brokowska, Joanna, et al.
Publicado: (2023)

The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II
por: Żuber, Zbigniew, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qlcsnh551sauooukr3fo0m4as0